Lee R. Brettman

Emergent Product Development Seattle discovers and develops biopharmaceutical products. It focuses on the discovery and development of novel medicines to treat inflammatory diseases and cancer. The company was founded by Peter A. Thompson, Jeffrey A. Ledbetter and Kendall M. Mohler in March 1999 and is headquartered in Seattle, WA.

Alnara Pharmaceuticals, Inc. develops and commercializes protein therapeutics for the treatment of metabolic diseases. It also develops liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT) for the treatment of exocrine pancreatic insufficiency (EPI). The company was founded by Christoph H. Westphal, Richard H. Aldrich and Alexy L. Margolin in 2008 and is headquartered in Boston, MA.

Dynogen Pharmaceuticals, Inc. develops and manufactures drugs. The company makes drugs for genitourinary and gastrointestinal disorders. It also makes drugs for constipation, Irritable Bowel Syndrome and overactive bladder. Dynogen Pharmaceuticals was founded by Lee R. Brettman in 2002 and is located in Waltham, MA.

Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA.

Schering-Plough Research Institute provides pharmaceutical research. The company is headquartered in Kenilworth, NJ.

LeukoSite, Inc. develops drugs for treatment of cancer and inflammatory diseases. It produces drugs to block autoimmune and viral diseases associated with malfunctioning leukocytes or white blood cells. The company was founded in 1992 and is located in Cambridge, MA.

Oxford Bioscience Partners is an Independent Venture Capital firm founded in 1992 by Edmund Martin Olivier, Alan G. Walton and Cornelius T. Ryan. The firm is headquartered in Boston.